Haemonetics Corp. (NYSE:HAE) shares shot up 6.4% during trading on Monday . The company traded as high as $33.11 and last traded at $32.27, with a volume of 503,152 shares changing hands. The stock had previously closed at $30.32.

A number of brokerages have recently commented on HAE. BTIG Research reiterated a “hold” rating on shares of Haemonetics Corp. in a research note on Tuesday, April 19th. Zacks Investment Research upgraded Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. Morgan Stanley reiterated a “hold” rating on shares of Haemonetics Corp. in a research note on Tuesday, May 3rd. Barrington Research dropped their price target on Haemonetics Corp. from $40.00 to $32.00 and set an “outperform” rating for the company in a research note on Tuesday, May 3rd. Finally, Benchmark Co. dropped their price target on Haemonetics Corp. from $35.00 to $28.00 and set a “hold” rating for the company in a research note on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $32.25.

The firm’s 50 day moving average price is $29.65 and its 200-day moving average price is $31.06. The company’s market capitalization is $1.71 billion.

Haemonetics Corp. (NYSE:HAE) last released its quarterly earnings data on Monday, August 1st. The company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. During the same period last year, the company earned $0.35 EPS. The company had revenue of $210 million for the quarter, compared to analyst estimates of $205.41 million. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. Analysts anticipate that Haemonetics Corp. will post $1.45 EPS for the current fiscal year.

A number of hedge funds and institutional investors have added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its position in Haemonetics Corp. by 5.1% in the fourth quarter. Principal Financial Group Inc. now owns 344,105 shares of the company’s stock worth $11,094,000 after buying an additional 16,768 shares in the last quarter. American Capital Management Inc. raised its position in Haemonetics Corp. by 1.6% in the fourth quarter. American Capital Management Inc. now owns 703,376 shares of the company’s stock worth $22,677,000 after buying an additional 10,920 shares in the last quarter. New York State Common Retirement Fund raised its position in Haemonetics Corp. by 3.0% in the fourth quarter. New York State Common Retirement Fund now owns 55,769 shares of the company’s stock worth $1,798,000 after buying an additional 1,600 shares in the last quarter. Rhumbline Advisers raised its position in Haemonetics Corp. by 1.3% in the fourth quarter. Rhumbline Advisers now owns 75,509 shares of the company’s stock worth $2,434,000 after buying an additional 935 shares in the last quarter. Finally, Comerica Bank raised its position in Haemonetics Corp. by 0.6% in the fourth quarter. Comerica Bank now owns 52,596 shares of the company’s stock worth $1,596,000 after buying an additional 321 shares in the last quarter.

Haemonetics Corporation is a healthcare company, which provides blood management solutions to its customers. The Company’s portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.